Literature DB >> 8389086

A new mechanism of oncogenic activation: E26 retroviral v-ets oncogene has inverted the C-terminal end of the transcription factor c-ets-1.

D Leprince1, P Crepieux, V Laudet, A Flourens, D Stehelin.   

Abstract

The v-ets-encoded domain in the P135gag-myb-ets transforming protein of the E26 retrovirus differs mainly from its cellular progenitor, p68c-ets-1 by two point mutations and by the replacement of the 13 last C-terminal amino acids present in c-ets-1 by 16 unrelated residues of previously unknown origin in v-ets. Here, we demonstrate that these v-ets C-terminal specific residues are in fact encoded by the opposite strand of the c-ets-1 C-terminus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389086     DOI: 10.1006/viro.1993.1330

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  4 in total

1.  Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif.

Authors:  L W Donaldson; J M Petersen; B J Graves; L P McIntosh
Journal:  EMBO J       Date:  1996-01-02       Impact factor: 11.598

2.  A residue of the ETS domain mutated in the v-ets oncogene is essential for the DNA-binding and transactivating properties of the ETS-1 and ETS-2 proteins.

Authors:  N Soudant; O Albagli; P Dhordain; A Flourens; D Stéhelin; D Leprince
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

3.  In vivo cooperation of two nuclear oncogenic proteins, P135gag-myb-ets and p61/63myc, leads to transformation and immortalization of chicken myelomonocytic cells.

Authors:  G Adelmant; B Quatannens; C Lagrou; N Wernert; G Torpier; S Saule; D Stehelin; V Laudet
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

4.  Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study.

Authors:  Yun-Fei Li; Qin-Zhang Wang; Tao-Tao Zhang; Lei Li; Jiang-Ping Wang; Guo-Fu Ding; DA-Lin He
Journal:  Oncol Lett       Date:  2013-11-01       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.